Catherine Stehman-Breen

Affiliate Associate Professor, Epidemiology



MD Medicine, University of Chicago, 1990
MS Epidemiology, University of Washington, 1996
BS Biology, Colby College, 1985



Chroma Medicine
201 Brookline Ave
Boston, MA 02118
View Website »


Catherine's research has focused on a ranges of areas including metabolic, cardiovascular, kidney and neurologic diseases including rare muscle disease. During her academic career, she managed the Clinical Research Training Program and developed the Epidemiology and Clinical Trials Research Program. Her research focused on bone and cardiovascular disease in renal disease patients. Catherine's subsequent work has been to bring innovative therapeutics to patients with serious illnesses. Characterizing disease epidemiology has been an important component of this work.

Catherine received her medical degree from University of Chicago in 1990. She completed her residency and fellowship training at the University of Washington where she also received a Masters of Science degree in Epidemiology. She spent six years as a Faculty member in the Division of Nephrology at University of Washington. Her primary responsibilities included managing the Clinical Research Training Program and the development of the Epidemiology and Clinical Trials Research Program. Her research focused on bone and cardiovascular disease in renal disease patients. Catherine is now Chief Executive Officer at Chroma Medicine. She also serves as an Independent Board member at Generation Bio, Tenaya Therapeutics and Dyne Therapeutics. Previously, she was Chief Research and Development Officer at Obsidian Therapeutics where she led discovery efforts for their engineered cell and gene therapies. Prior to that, Catherine was an Entrepreneur in Residence at Atlas Venture and Chief Medical Officer at Sarepta Therapeutics. In addition, Catherine held leadership roles of increasing responsibility at Regeneron and Amgen.

Research Interests

• Fasinumab: A monoclonal antibody to nerve growth factor and a potential treatment for chronic pain

The epidemiology of bone disease in patients with Duchenne muscular dystrophy.

Recent Publications (PubMed)

Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis.
(2013 Oct)
Pharmacoepidemiol Drug Saf 22(10): 1107-14
Xue F, Ma H, Stehman-Breen C, Haller C, Katz L, Wagman RB, Critchlow CW, Denosumab Global Safety Assessment Team

Effects of denosumab on fracture and bone mineral density by level of kidney function.
(2011 Aug)
J Bone Miner Res 26(8): 1829-35
Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, Ebeling PR, Franek E, Yang YC, Egbuna OI, Boonen S, Miller PD

Chronic kidney disease and the risk of end-stage renal disease versus death.
(2011 Apr)
J Gen Intern Med 26(4): 379-85
Dalrymple LS, Katz R, Kestenbaum B, Shlipak MG, Sarnak MJ, Stehman-Breen C, Seliger S, Siscovick D, Newman AB, Fried L

Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
(2008 Jun)
Am J Geriatr Pharmacother 6(2): 49-60
Silver MR, Agarwal A, Krause M, Lei L, Stehman-Breen C

Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.
(2008 Jul)
Clin J Am Soc Nephrol 3(4): 1077-83
Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD

Show complete publication list

In the News

No news articles at this time.